[R3D]GexIVA[1,4]
General Information
DCTPep ID DCTPep06263
Peptide Name [R3D]GexIVA[1,4]
Sequence TCDSSGRYCRSPYDRRRRYCRRITDACV
Sequence Length 28
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
ACP Cancer targeted peptides α9α10nAChR inhibitor
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target α9α10nAChR
Affinity Not available
Mechanism Specifically block the α9α10nAChR
Structure Information
PDB ID Not available
Predicted Structure Not available
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Cys2<--->Cys27; Cys9<--->Cys20
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C137H224N52O43S4
Absent amino acids EFHKLMNQW
Theoretical pI 9.57
Acidic residues 3
Basic residues 8
Polar residues 13
Molecular weight (Average) 3415.85
Molecular weight (Monoisotopic) 3413.58
Common amino acids R
Net charge 5
Instability index (II) 156.87
Aliphatic index 27.86
Grand average of hydropathicity (GRAVY) -1.275
Half Life
7.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 4720
Abs 0.1% (=1 g/l) 1.382, assuming all pairs of Cys residues form cystines
Ext. coefficient 4470
Abs 0.1% (=1 g/l) 1.309, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID CN112010972A
Patent Title Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof
Other Iinformation Not available
Other Published ID Not available